Botryoid-type embryonal rhabdomyosarcoma of the vagina

Summary

Botryoid-type embryonal rhabdomyosarcoma of the vagina (MONDO:0003994) is a disease. A subtype of botryoid rhabdomyosarcoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	botryoid-type embryonal rhabdomyosarcoma of the vagina
Mondo ID	MONDO:0003994
DOID	DOID:6788
NCIT	C40268
UMLS	C1511275
MedGen	267758
GARD	0023767
Anatomy (UBERON)	UBERON:0000996
Is cancer (heuristic)	no

Also known as: botryoid rhabdomyosarcoma of vagina · botryoid-type embryonal rhabdomyosarcoma of the vagina · sarcoma Botryoides of the vagina · vagina botryoid rhabdomyosarcoma

Disease family

This is a subtype of botryoid rhabdomyosarcoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › sarcoma › soft tissue sarcoma › rhabdomyosarcoma › embryonal rhabdomyosarcoma › botryoid rhabdomyosarcoma › botryoid-type embryonal rhabdomyosarcoma of the vagina

Related subtypes (2): childhood botryoid rhabdomyosarcoma, adult botryoid rhabdomyosarcoma

Subtypes (2): childhood vagina botryoid rhabdomyosarcoma, adult vagina botryoid embryonal rhabdomyosarcoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.